These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38893136)

  • 1. Oncological Outcomes and Patterns of Recurrence after the Surgical Resection of an Invasive Intraductal Papillary Mucinous Neoplasm versus Primary Pancreatic Ductal Adenocarcinoma: An Analysis from the German Cancer Registry Group of the Society of German Tumor Centers.
    Abdalla TSA; Duhn J; Klinkhammer-Schalke M; Zeissig SR; Kleihues-van Tol K; Honselmann KC; Braun R; Kist M; Bolm L; von Fritsch L; Lapshyn H; Litkevych S; Hummel R; Zemskov S; Wellner UF; Keck T; Deichmann S
    Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma.
    Fogliati A; Zironda A; Fiorentini G; Adjei S; Amro A; Starlinger PP; Grotz TE; Warner SG; Smoot RL; Thiels CA; Kendrick ML; Cleary SP; Truty MJ
    Ann Surg Oncol; 2024 Apr; 31(4):2632-2639. PubMed ID: 38319513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invasive IPMN relapse later and more often in lungs in comparison to pancreatic ductal adenocarcinoma.
    Capretti G; Nebbia M; Gavazzi F; Nappo G; Ridolfi C; Sollai M; Spaggiari P; Bozzarelli S; Carrara S; Luberto A; Zerbi A
    Pancreatology; 2022 Sep; 22(6):782-788. PubMed ID: 35701318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.
    Sohn TA; Yeo CJ; Cameron JL; Hruban RH; Fukushima N; Campbell KA; Lillemoe KD
    Ann Surg; 2004 Jun; 239(6):788-97; discussion 797-9. PubMed ID: 15166958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
    Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
    Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome after surgery for invasive intraductal papillary mucinous neoplasia compared to conventional pancreatic ductal adenocarcinoma - A Swedish nationwide register-based study.
    Holmberg M; Radkiewicz C; Strömberg C; Öman M; Ghorbani P; Löhr JM; Sparrelid E
    Pancreatology; 2023 Jan; 23(1):90-97. PubMed ID: 36522260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of para-aortic lymph node status in resected pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous neoplasm - Time to consider a reclassification?
    Linder S; Holmberg M; Engstrand J; Ghorbani P; Sparrelid E
    Surg Oncol; 2022 May; 41():101735. PubMed ID: 35287096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome after resection for invasive intraductal papillary mucinous neoplasia is similar to conventional pancreatic ductal adenocarcinoma.
    Holmberg M; Ghorbani P; Gilg S; Del Chiaro M; Arnelo U; Löhr JM; Sparrelid E
    Pancreatology; 2021 Oct; 21(7):1371-1377. PubMed ID: 34426077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Outcomes following Resection of Adenocarcinoma Arising from Intraductal Papillary Mucinous Neoplasm (A-IPMN) versus Pancreatic Ductal Adenocarcinoma (PDAC): A Propensity-score Matched Analysis.
    Lucocq J; Halle-Smith J; Haugk B; Joseph N; Hawkyard J; Lye J; Parkinson D; White S; Mownah O; Zen Y; Menon K; Furukawa T; Inoue Y; Hirose Y; Sasahira N; Mittal A; Samra J; Sheen A; Feretis M; Balakrishnan A; Ceresa C; Davidson B; Pande R; Dasari BVM; Tanno L; Karavias D; Helliwell J; Young A; Marks K; Nunes Q; Urbonas T; Silva M; Gordon-Weeks A; Barrie J; Gomez D; van Laarhoven S; Nawara H; Doyle J; Bhogal R; Harrison E; Roalso M; Ciprani D; Aroori S; Ratnayake B; Koea J; Capurso G; Bellotti R; Stättner S; Alsaoudi T; Bhardwaj N; Rajesh S; Jeffery F; Connor S; Cameron A; Jamieson N; Soreide K; Gill AJ; Roberts K; Pandanaboyana S
    Ann Surg; 2024 Mar; ():. PubMed ID: 38516777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Invasive Pancreatic Ductal Adenocarcinoma versus Intraductal Papillary Mucinous Neoplasm: A National Cancer Database Analysis.
    Ziogas IA; Rodriguez Franco S; Schmoke N; Meguid C; Murphy C; Al-Musawi M; Alexopoulos SP; Schulick RD; Del Chiaro M
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inferior head resection of the pancreas for intraductal papillary mucinous neoplasms.
    Nakagohri T; Kinoshita T; Konishi M; Takahashi S; Gotohda N; Kobayashi S; Kojima M; Miyauchi H; Asano T
    J Hepatobiliary Pancreat Sci; 2010 Nov; 17(6):798-802. PubMed ID: 19727540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
    McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
    Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival.
    Gavazzi F; Capretti G; Giordano L; Ridolfi C; Spaggiari P; Sollai M; Carrara S; Nappo G; Bozzarelli S; Zerbi A
    Dig Liver Dis; 2022 Jun; 54(6):826-833. PubMed ID: 34219044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasive intraductal oncocytic papillary neoplasms (IOPN) and adenocarcimoma arising from intraductal papillary mucinous neoplasms (A-IPMN) of the pancreas: comparative analysis of clinicopathological features, patterns of recurrence and survival: a multicentre study.
    Lucocq J; Haugk B; Joseph N; Hawkyard J; White S; Mownah O; Menon K; Furukawa T; Inoue Y; Hirose Y; Sasahira N; Mittal A; Samra J; Sheen A; Feretis M; Balakrishnan A; Ceresa C; Davidson B; Pande R; Dasari BVM; Tanno L; Karavias D; Helliwell J; Young A; Nunes Q; Urbonas T; Silva M; Gordon-Weeks A; Barrie J; Gomez D; van Laarhoven S; Nawara H; Doyle J; Bhogal R; Harrison E; Roalso M; Zaharia C; Ciprani D; Aroori S; Ratnayake B; Koea J; Capurso G; Bellotti R; Stättner S; Alsaoudi T; Bhardwaj N; Jeffery F; Connor S; Cameron A; Jamieson N; Roberts K; Soreide K; Gill AJ; Pandanaboyana S
    HPB (Oxford); 2024 Jul; ():. PubMed ID: 39084948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of spatio-temporal recurrence pattern on overall survival for invasive intraductal papillary mucinous neoplasia - A comparison with pancreatic ductal adenocarcinoma.
    Holmberg M; Linder S; Kordes M; Liljefors M; Ghorbani P; Löhr JM; Sparrelid E
    Pancreatology; 2022 Jun; 22(5):598-607. PubMed ID: 35501218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas.
    Poultsides GA; Reddy S; Cameron JL; Hruban RH; Pawlik TM; Ahuja N; Jain A; Edil BH; Iacobuzio-Donahue CA; Schulick RD; Wolfgang CL
    Ann Surg; 2010 Mar; 251(3):470-6. PubMed ID: 20142731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes.
    Wasif N; Bentrem DJ; Farrell JJ; Ko CY; Hines OJ; Reber HA; Tomlinson JS
    Cancer; 2010 Jul; 116(14):3369-77. PubMed ID: 20564064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage.
    Waters JA; Schnelldorfer T; Aguilar-Saavedra JR; Chen JH; Yiannoutsos CT; Lillemoe KD; Farnell MB; Sarr MG; Schmidt CM
    J Am Coll Surg; 2011 Aug; 213(2):275-83. PubMed ID: 21601488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management and outcomes of intraductal papillary mucinous neoplasms.
    Hipp J; Mohamed S; Pott J; Sick O; Makowiec F; Hopt UT; Fichtner-Feigl S; Wittel UA
    BJS Open; 2019 Aug; 3(4):490-499. PubMed ID: 31388641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma.
    Rezaee N; Barbon C; Zaki A; He J; Salman B; Hruban RH; Cameron JL; Herman JM; Ahuja N; Lennon AM; Weiss MJ; Wood LD; Wolfgang CL
    HPB (Oxford); 2016 Mar; 18(3):236-46. PubMed ID: 27017163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.